A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia
Gespeichert in:
| Veröffentlicht in: | American journal of hematology 2019-11, Vol.94 (11), p.E291-E294 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | E294 |
|---|---|
| container_issue | 11 |
| container_start_page | E291 |
| container_title | American journal of hematology |
| container_volume | 94 |
| creator | Tomlinson, Benjamin K. Tuscano, Joseph M. Abedi, Mehrdad Welborn, Jeanna Arora, Mili O'Donnell, Robert T. Wun, Ted Jonas, Brian A. |
| description | |
| doi_str_mv | 10.1002/ajh.25605 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2268574149</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2268574149</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3885-13d54a0b3b94281a62f2569b5d53f4b2eeffe3ce97487c7015068a9efa13fac43</originalsourceid><addsrcrecordid>eNp10U9vFCEYBnBiNHatHvwChsSLPWzLn4GB46ap7ZomXvRMgHlxWWeGEWZSx08vutWDiSc4_Hjy8j4IvabkkhLCruzxcMmEJOIJ2lCi5VZJwZ6iDeGS1jvRZ-hFKUdCKG0UeY7OOOWtJlRu0LDD08EWwPs9LvPSrTgF7FKe4UcaosNxxD4NLo52jmnED3E-4Am-rL2docN9nFJJg-1xl76nvLjo64OQMrZ-mQEPK_QpVgfLVxiifYmeBdsXePV4nqPP728-Xd9t7z_e7q9391vPlRJbyjvRWOK40w1T1EoW6ve0E53goXEMIATgHnTbqNa3hAoildUQLOXB-oafo3en3CmnbwuU2QyxeOh7O0JaimFMKtE2tNGVvv2HHtOSxzqdYZwIqVrNZVUXJ-VzKiVDMFOOg82rocT86sDUDszvDqp985i4uAG6v_LP0iu4OoGH2MP6_ySz-3B3ivwJezWQvg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2305687936</pqid></control><display><type>article</type><title>A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><creator>Tomlinson, Benjamin K. ; Tuscano, Joseph M. ; Abedi, Mehrdad ; Welborn, Jeanna ; Arora, Mili ; O'Donnell, Robert T. ; Wun, Ted ; Jonas, Brian A.</creator><creatorcontrib>Tomlinson, Benjamin K. ; Tuscano, Joseph M. ; Abedi, Mehrdad ; Welborn, Jeanna ; Arora, Mili ; O'Donnell, Robert T. ; Wun, Ted ; Jonas, Brian A.</creatorcontrib><identifier>ISSN: 0361-8609</identifier><identifier>EISSN: 1096-8652</identifier><identifier>DOI: 10.1002/ajh.25605</identifier><identifier>PMID: 31379016</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject><![CDATA[Acute myeloid leukemia ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bortezomib ; Bortezomib - administration & dosage ; Bortezomib - adverse effects ; Doxorubicin ; Doxorubicin - administration & dosage ; Doxorubicin - adverse effects ; Doxorubicin - analogs & derivatives ; Febrile Neutropenia - chemically induced ; Female ; Hematology ; Humans ; Hydroxyurea - administration & dosage ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute - drug therapy ; Male ; Middle Aged ; Myeloid leukemia ; Neoplastic Cells, Circulating ; Polyethylene Glycols - administration & dosage ; Polyethylene Glycols - adverse effects ; Progression-Free Survival ; Proteasome Inhibitors - administration & dosage ; Proteasome Inhibitors - adverse effects ; Targeted cancer therapy ; Treatment Outcome]]></subject><ispartof>American journal of hematology, 2019-11, Vol.94 (11), p.E291-E294</ispartof><rights>2019 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3885-13d54a0b3b94281a62f2569b5d53f4b2eeffe3ce97487c7015068a9efa13fac43</citedby><cites>FETCH-LOGICAL-c3885-13d54a0b3b94281a62f2569b5d53f4b2eeffe3ce97487c7015068a9efa13fac43</cites><orcidid>0000-0002-4921-5809 ; 0000-0002-2407-0973</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fajh.25605$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fajh.25605$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31379016$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tomlinson, Benjamin K.</creatorcontrib><creatorcontrib>Tuscano, Joseph M.</creatorcontrib><creatorcontrib>Abedi, Mehrdad</creatorcontrib><creatorcontrib>Welborn, Jeanna</creatorcontrib><creatorcontrib>Arora, Mili</creatorcontrib><creatorcontrib>O'Donnell, Robert T.</creatorcontrib><creatorcontrib>Wun, Ted</creatorcontrib><creatorcontrib>Jonas, Brian A.</creatorcontrib><title>A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia</title><title>American journal of hematology</title><addtitle>Am J Hematol</addtitle><subject>Acute myeloid leukemia</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bortezomib</subject><subject>Bortezomib - administration & dosage</subject><subject>Bortezomib - adverse effects</subject><subject>Doxorubicin</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - adverse effects</subject><subject>Doxorubicin - analogs & derivatives</subject><subject>Febrile Neutropenia - chemically induced</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Hydroxyurea - administration & dosage</subject><subject>Kaplan-Meier Estimate</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myeloid leukemia</subject><subject>Neoplastic Cells, Circulating</subject><subject>Polyethylene Glycols - administration & dosage</subject><subject>Polyethylene Glycols - adverse effects</subject><subject>Progression-Free Survival</subject><subject>Proteasome Inhibitors - administration & dosage</subject><subject>Proteasome Inhibitors - adverse effects</subject><subject>Targeted cancer therapy</subject><subject>Treatment Outcome</subject><issn>0361-8609</issn><issn>1096-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10U9vFCEYBnBiNHatHvwChsSLPWzLn4GB46ap7ZomXvRMgHlxWWeGEWZSx08vutWDiSc4_Hjy8j4IvabkkhLCruzxcMmEJOIJ2lCi5VZJwZ6iDeGS1jvRZ-hFKUdCKG0UeY7OOOWtJlRu0LDD08EWwPs9LvPSrTgF7FKe4UcaosNxxD4NLo52jmnED3E-4Am-rL2docN9nFJJg-1xl76nvLjo64OQMrZ-mQEPK_QpVgfLVxiifYmeBdsXePV4nqPP728-Xd9t7z_e7q9391vPlRJbyjvRWOK40w1T1EoW6ve0E53goXEMIATgHnTbqNa3hAoildUQLOXB-oafo3en3CmnbwuU2QyxeOh7O0JaimFMKtE2tNGVvv2HHtOSxzqdYZwIqVrNZVUXJ-VzKiVDMFOOg82rocT86sDUDszvDqp985i4uAG6v_LP0iu4OoGH2MP6_ySz-3B3ivwJezWQvg</recordid><startdate>201911</startdate><enddate>201911</enddate><creator>Tomlinson, Benjamin K.</creator><creator>Tuscano, Joseph M.</creator><creator>Abedi, Mehrdad</creator><creator>Welborn, Jeanna</creator><creator>Arora, Mili</creator><creator>O'Donnell, Robert T.</creator><creator>Wun, Ted</creator><creator>Jonas, Brian A.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4921-5809</orcidid><orcidid>https://orcid.org/0000-0002-2407-0973</orcidid></search><sort><creationdate>201911</creationdate><title>A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia</title><author>Tomlinson, Benjamin K. ; Tuscano, Joseph M. ; Abedi, Mehrdad ; Welborn, Jeanna ; Arora, Mili ; O'Donnell, Robert T. ; Wun, Ted ; Jonas, Brian A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3885-13d54a0b3b94281a62f2569b5d53f4b2eeffe3ce97487c7015068a9efa13fac43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Acute myeloid leukemia</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bortezomib</topic><topic>Bortezomib - administration & dosage</topic><topic>Bortezomib - adverse effects</topic><topic>Doxorubicin</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - adverse effects</topic><topic>Doxorubicin - analogs & derivatives</topic><topic>Febrile Neutropenia - chemically induced</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Hydroxyurea - administration & dosage</topic><topic>Kaplan-Meier Estimate</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myeloid leukemia</topic><topic>Neoplastic Cells, Circulating</topic><topic>Polyethylene Glycols - administration & dosage</topic><topic>Polyethylene Glycols - adverse effects</topic><topic>Progression-Free Survival</topic><topic>Proteasome Inhibitors - administration & dosage</topic><topic>Proteasome Inhibitors - adverse effects</topic><topic>Targeted cancer therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tomlinson, Benjamin K.</creatorcontrib><creatorcontrib>Tuscano, Joseph M.</creatorcontrib><creatorcontrib>Abedi, Mehrdad</creatorcontrib><creatorcontrib>Welborn, Jeanna</creatorcontrib><creatorcontrib>Arora, Mili</creatorcontrib><creatorcontrib>O'Donnell, Robert T.</creatorcontrib><creatorcontrib>Wun, Ted</creatorcontrib><creatorcontrib>Jonas, Brian A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tomlinson, Benjamin K.</au><au>Tuscano, Joseph M.</au><au>Abedi, Mehrdad</au><au>Welborn, Jeanna</au><au>Arora, Mili</au><au>O'Donnell, Robert T.</au><au>Wun, Ted</au><au>Jonas, Brian A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia</atitle><jtitle>American journal of hematology</jtitle><addtitle>Am J Hematol</addtitle><date>2019-11</date><risdate>2019</risdate><volume>94</volume><issue>11</issue><spage>E291</spage><epage>E294</epage><pages>E291-E294</pages><issn>0361-8609</issn><eissn>1096-8652</eissn><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>31379016</pmid><doi>10.1002/ajh.25605</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-4921-5809</orcidid><orcidid>https://orcid.org/0000-0002-2407-0973</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0361-8609 |
| ispartof | American journal of hematology, 2019-11, Vol.94 (11), p.E291-E294 |
| issn | 0361-8609 1096-8652 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2268574149 |
| source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection) |
| subjects | Acute myeloid leukemia Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bortezomib Bortezomib - administration & dosage Bortezomib - adverse effects Doxorubicin Doxorubicin - administration & dosage Doxorubicin - adverse effects Doxorubicin - analogs & derivatives Febrile Neutropenia - chemically induced Female Hematology Humans Hydroxyurea - administration & dosage Kaplan-Meier Estimate Leukemia, Myeloid, Acute - drug therapy Male Middle Aged Myeloid leukemia Neoplastic Cells, Circulating Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects Progression-Free Survival Proteasome Inhibitors - administration & dosage Proteasome Inhibitors - adverse effects Targeted cancer therapy Treatment Outcome |
| title | A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T12%3A20%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20II%20study%20of%20bortezomib%20in%20combination%20with%20pegylated%20liposomal%20doxorubicin%20for%20acute%20myeloid%20leukemia&rft.jtitle=American%20journal%20of%20hematology&rft.au=Tomlinson,%20Benjamin%20K.&rft.date=2019-11&rft.volume=94&rft.issue=11&rft.spage=E291&rft.epage=E294&rft.pages=E291-E294&rft.issn=0361-8609&rft.eissn=1096-8652&rft_id=info:doi/10.1002/ajh.25605&rft_dat=%3Cproquest_cross%3E2268574149%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2305687936&rft_id=info:pmid/31379016&rfr_iscdi=true |